Evidence map›Paper›PMID 40877791›Full record

SynthesisBMC cardiovascular disorders2025

Carbohydrate antigen 125 and clinical outcomes in heart failure: systematic review and meta-analysis.

Seyed Morteza Pourfaraji, Fatemeh Ojaghi Shirmard, Dorsa Salabat, Danyal Salabat, Zahra Mehdipournamdar, Toshiki Kuno, Anil Harrison, Marc Samsky, Kaveh Hosseini

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Seyed Morteza PourfarajiCardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh Ojaghi ShirmardCardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Dorsa SalabatCardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Danyal SalabatStudent Research Committee, Arak University of Medical Sciences, Arak, Iran.
Zahra MehdipournamdarDivision of cardiology, University of Oklahoma Health Sciences Center, Oklahoma, USA.
Toshiki KunoCardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Anil HarrisonFlorida West Primary Care, Pensacola, FL, USA.
Marc SamskyYale New Haven Hospital, New Haven, CT, USA.
Kaveh HosseiniCardiovascular Diseases Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. kaveh_hosseini130@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCarbohydrate Antigen 125 (CA125) has emerged as a potential biomarker in patients with heart failure (HF). This meta-analysis comprehensively evaluates the association between CA125 levels and clinical outcomes across HF populations.

methodsWe conducted this study based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). We systematically searched PubMed, Scopus, Web of Science, and Embase libraries up to April 2025. We selected the original English-language investigations that reported the association between CA125 levels and clinical outcomes in cases with HF. The random-effects model and Hartung-Knapp-Sidik-Jonkman method were used to pool effect sizes and report summary statistics. The current review was registered in PROSPERO (CRD420251023141).

resultsA total of 20,458 cases were included from 29 studies, with an average age of 70.3 years, and 36.1% of cases were women. The average cut-off level was 37.78 U/mL, and 35 U/mL was mainly used as the CA125 cut-off level. A meta-analysis of nine studies that reported the risk of experiencing endpoint events (death or HF-related hospitalization) showed significantly higher risk (HR 2.23, 95% CI 1.69-2.93; p < 0.01; I

conclusionThe current review findings revealed CA125 as a significant prognostic factor of mortality and hospitalization risks in HF population. Furthermore, CA125 could be a non-invasive and operator-independent tool for evaluating disease severity and monitoring response to therapy. We suggested CA125 for monitoring various treatments in individuals with HF, specifically diuretic therapy. Further prospective studies are needed to determine the optimal cut-off for CA125 levels in HF.

Indexed as

CA-125 AntigenHeart FailureMembrane ProteinsAgedAged, 80 and overBiomarkersFemaleHospitalizationHumansMaleMiddle AgedPredictive Value of TestsPrognosisRisk AssessmentRisk FactorsBiomarkersCA-125 AntigenMembrane ProteinsMUC16 protein, humanBiomarkerCA125 antigenCardiovascular diseaseMyocardial failureVentricular dysfunction

Identifiers

PMID40877791
PMCPMC12392669

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.